TNF-α targeted therapeutic approaches in patients with hematologic malignancies

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1975 • 3,051 citations

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

1999 • 2,117 citations

Cancer statistics, 1997

1997 • 2,045 citations

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

2000 • 1,757 citations

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1997 • 1,651 citations

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1998 • 1,642 citations

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

2000 • 1,463 citations

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors

1986 • 1,433 citations

Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?

2001 • 1,237 citations

Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein

1996 • 1,217 citations

Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis

2000 • 1,211 citations

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

1993 • 1,058 citations

An interleukin 1 like factor stimulates bone resorption in vitro

1983 • 1,017 citations

TNF? and the TNF receptor superfamily: Structure-function relationship(s)

2000 • 983 citations

A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins

1990 • 977 citations

Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor

1990 • 918 citations

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

2000 • 868 citations

Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines

1997 • 838 citations

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

1993 • 837 citations

Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides

2001 • 813 citations

Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

1998 • 761 citations

Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis

2001 • 720 citations

Gene expression of tumor necrosis factor [alpha ] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

2001 • 677 citations

Report of an international working group to standardize response criteria for myelodysplastic syndromes

2000 • 673 citations

Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.

1987 • 609 citations

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.

1990 • 509 citations

Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes [see comments]

1995 • 445 citations

Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure

1999 • 397 citations

Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure

2001 • 386 citations

Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

1998 • 342 citations

Onset of multiple sclerosis associated with anti-TNF therapy

2001 • 316 citations

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

2001 • 289 citations

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation

2001 • 288 citations

Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

1998 • 276 citations

Transfer of Tumor Necrosis Factor-α to Rat Lung Induces Severe Pulmonary Inflammation and Patchy Interstitial Fibrogenesis with Induction of Transforming Growth Factor-β1 and Myofibroblasts

1998 • 263 citations

Isolation and characterization of a tumor necrosis factor binding protein from urine

1989 • 249 citations

Differential Effects of Anti-Fas Ligand and Anti-Tumor Necrosis Factor α Antibodies on Acute Graft-Versus-Host Disease Pathologies

1998 • 228 citations

Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety

2001 • 220 citations

Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration.

1995 • 206 citations

Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F)

1995 • 198 citations

Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes

1996 • 182 citations

Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease

1992 • 176 citations

Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

2001 • 165 citations

Production of cytokines by bone marrow cells obtained from patients with multiple myeloma

1989 • 156 citations

Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6.

1991 • 154 citations

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1995 • 152 citations

TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies

2000 • 143 citations

Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease

1992 • 139 citations

Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis

1999 • 130 citations

Inhibitors of tumor necrosis factor for rheumatoid arthritis.

1999 • 125 citations

Pentoxifylline Prevents Tumor Necrosis Factor-induced Lung Injury

1989 • 122 citations

Tumor Necrosis Factor Signal Transduction

1989 • 114 citations

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis

2001 • 112 citations

Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease1

2002 • 111 citations

Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes

2000 • 106 citations

Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

1999 • 100 citations

TNF-α, PDGF, and TGF-β1 Expression by Primary Mouse Bronchiolar-Alveolar Epithelial and Mesenchymal Cells: TNF-α Induces TGF-β1

2001 • 100 citations

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study

2002 • 89 citations

Indication of an involvement of interleukin-1 beta converting enzyme- like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes

1996 • 89 citations

Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.

1993 • 88 citations

TNF and IL‐6 are potent growth factors for OH‐2, a novel human myeloma cell line

1994 • 80 citations

Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone

2000 • 75 citations

Etanercept (Enbrel): update on therapeutic use

2000 • 72 citations

TNF receptor p55 controls early acute graft-versus-host disease.

1997 • 72 citations

SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR (p75) FUSION PROTEIN (ENBREL) AS A THERAPY FOR RHEUMATOID ARTHRITIS

1998 • 71 citations

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment

2003 • 63 citations

APOPTOSIS-INDUCED BY TRAIL AND TNF-α IN HUMAN MULTIPLE MYELOMA CELLS IS NOT BLOCKED BY BCL-2

1999 • 61 citations

Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.

1996 • 55 citations

Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients

1990 • 53 citations

Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.

1996 • 47 citations

Etanercept and urticaria in patients with juvenile idiopathic arthritis.

2000 • 46 citations

EVALUATION OF RECOMBINANT HUMAN SOLUBLE DIMERIC TUMOR NECROSIS FACTOR RECEPTOR FOR PREVENTION OF OKT3-ASSOCIATED ACUTE CLINICAL SYNDROME1,2

1996 • 45 citations

Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays

2000 • 39 citations

Aza analogues of thalidomide

2001 • 37 citations

Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients

1990 • 37 citations

Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.

1993 • 35 citations

Autocrine Growth by Two Cytokines, Interleukin-6 and Tumor Necrosis Factor Alpha, in the Myeloma Cell Line KHM-1A

1990 • 31 citations

THE ROLE OF THE TWO TNF RECEPTORS IN PROLIFERATION, NF-κB ACTIVATION AND DISCRIMINATION BETWEEN TNF AND LTαSIGNALLING IN THE HUMAN MYELOMA CELL LINE OH-2

1996 • 27 citations

Potential role for phosphatidic acid in mediating the inflammatory responses to TNF alpha and IL-1 beta.

1994 • 26 citations

Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha?

2000 • 22 citations

Cytokine gene activity in AML cells in vivo in patients

1998 • 21 citations

New insights in the clinical biology of multiple myeloma.

1997 • 17 citations

The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia

1999 • 16 citations

An unusual cause of progressive heart failure

2001 • 7 citations

The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.

1999 • 7 citations